Dr. Trainor brings 30 years of experience in the Biotechnology and Pharmaceutical Industries. He has expertise in overall drug discovery strategy and execution, medicinal chemistry, and the application of transformative technologies. Leading teams of over 100 scientists, he has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. His team provided key discovery support that enabled the successful launch of SustivaTM for HIV disease.
Dr. Trainor joins BioMotiv after leaving Bristol Myers Squibb Company as Vice President of Oncology and Early Discovery Chemistry. He was responsible for all aspects of medicinal chemistry for the oncology area as well as hit-to-leads activities in support of all therapeutic areas. Prior to being merged into Bristol Myers Squibb, Dr. Trainor was Executive Director for Medicinal Chemistry at Dupont/Dupont Merck Pharmaceuticals. His key contribution from that period was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing. This breakthrough technology was subsequently employed in the sequencing of the human genome, and In 2011, Trainor won the American Chemical Society’s Heroes of Chemistry Award for his work on DNA sequencing.
Dr. Trainor has lectured widely, is an inventor on nearly 20 issued US patents, and has over 80 peer-reviewed publications. He has served on Grant Review Study Sections for the NIH and DOE. Dr. Trainor did his undergraduate work at Stevens Institute of Technology, received his PhD in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.